Potential role of probiotics on colorectal cancer prevention

BMC Surgery

Volumn 12, Issue SUPPL. 1, 2012, Pages

  Uccello, Mario ^a   Malaguarnera, Giulia ^a   Basile, Francesco ^a   Dagata, Velia ^a   Malaguarnera, Michele ^a   Bertino, Gaetano ^a   Vacante, Marco ^a   Drago, Filippo ^a   Biondi, Antonio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; PROTEIN TYROSINE KINASE; TUMOR MARKER;

APOPTOSIS; CELL DIFFERENTIATION; COLORECTAL TUMOR; DRUG ANTAGONISM; FERMENTATION; HUMAN; IMMUNOLOGY; INTESTINE MUCOSA; LARGE INTESTINE; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; REVIEW;

APOPTOSIS; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; FERMENTATION; HUMANS; INTESTINAL MUCOSA; INTESTINE, LARGE; PROBIOTICS; PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84869405047     PISSN: None     EISSN: 14712482     Source Type: Journal    
DOI: 10.1186/1471-2482-12-S1-S35     Document Type: Article

References (111)

1. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Haggar FA, Boushey RP, Clin Colon Rectal Surg 2009 22 191 197 10.1055/s-0029-1242458 21037809
2. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Larsson SC, Wolk A, Int J Cancer 2006 119 2657 2664 10.1002/ijc.22170 16991129 (Pubitemid 44691322)
3. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Riboli E, Norat T, Am J Clin Nutr 2003 78 559S 569S 12936950 (Pubitemid 40012550)
4. The effects of probiotics on colon cancer development. Rafter J, Nutr Res Rev 2004 17 277 284 10.1079/NRR200484 19079931
5. Bacteria in the gut: friends and foes and how to alter the balance. Rastall RA, J Nutr 2004 134 2022S 2026S 15284393 (Pubitemid 39031270)
6. Evaluation of health and nutritional properties of probiotics in food, including powder milk with live lactic acid bacteria. FAO, WHO, Food and Agricultural Organization of United Nations and World Health Organization Expert Consultation Report 2001 http://www.who.int/foodsafety/publications/fs- management/en/probiotics.pdf
7. Gastrointestinal microflora, food components and colon cancer prevention. Davis CD, Milner JA, J Nutr Biochem 2009 20 743 752 10.1016/j.jnutbio.2009.06. 001 19716282
8. Therapeutical use of probiotic formulations in clinical practice. Iannitti T, Palmieri B, Clin Nutr 2010 29 701 725 10.1016/j.clnu.2010.05.004 20576332
9. Prebiotics: the concept revisited. Roberfroid M, J Nutr 2007 137 830S 837S 17311983 (Pubitemid 46397526)
10. Synbiotic intervention of Bifidobacterium lactis and resistant starch protects against colorectal cancer development in rats. Le Leu RK, Hu Y, Brown IL, Woodman RJ, Young GP, Carcinogenesis 2010 31 246 251 10.1093/carcin/bgp197 19696163
11. Lactic acid bacteria and their effect on the immune system. Perdigán G, Fuller R, Raya R, Curr Issues Intest Microbiol 2001 2 27 42 11709854 (Pubitemid 32401085)
12. Ability of probiotic Lactobacillus casei DN 114001 to bind or/and metabolise heterocyclic aromatic amines in vitro. Nowak A, Libudzisz Z, Eur J Nutr 2009 48 419 427 10.1007/s00394-009-0030-1 19448966
13. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Rowland IR, Rumney CJ, Coutts JT, Lievense LC, Carcinogenesis 1998 19 281 285 10.1093/carcin/19.2.281 9498277 (Pubitemid 28375422)
14. UDP-glucuronosyltransferases: a family of detoxifying enzymes. Tephly TR, Burchell B, Trends Pharmacol Sci 1990 11 276 279 10.1016/0165-6147(90)90008-V 2117826 (Pubitemid 20205384)
15. Effect of high-risk diets for colon carcinogenesis on intestinal mucosal and bacterial beta-glucuronidase activity in F344 rats. Reddy BS, Mangat S, Weisburger JH, Wynder EL, Cancer Res 1977 37 3533 3536 908005 (Pubitemid 8198408)
16. The role of colon anaerobes in the metabolism of bile acids and steroids, and its relation to colon cancer. Hill MJ, Cancer 1975 36 2387 2400 764958
17. The relationship between diet and rat fecal bacterial enzymes implicated in colon cancer. Goldin BR, Gorbach SL, J Natl Cancer Inst 1976 57 371 375 1003518
18. Alterations of the intestinal microflora by diet, oral antibiotics, and Lactobacillus: decreased production of free amines from aromatic nitro compounds, azo dyes, and glucuronides. Goldin BR, Gorbach SL, J Natl Cancer Inst 1984 73 689 695 6433097 (Pubitemid 14000202)
19. Reduction of beta-glucuronidase and nitroreductase activity by yoghurt in a murine colon cancer model. de Moreno de LeBlanc A, Perdigán G, Biocell 2005 29 15 24 15954463
20. The effect of milk and lactobacillus feeding on human intestinal bacterial enzyme activity. Goldin BR, Gorbach SL, Am J Clin Nutr 1984 39 756 761 6424430 (Pubitemid 14101232)
21. Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. Goldin BR, Swenson L, Dwyer J, Sexton M, Gorbach SL, J Natl Cancer Inst 1980 64 255 261 6766508 (Pubitemid 10174170)
22. Lactobacilli, anticarcinogenic activities and human intestinal microflora. Lidbeck A, Nord CE, Gustafsson JA, Rafter J, Eur J Cancer Prev 1992 1 341 353 10.1097/00008469-199208000-00002 1463986
23. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK, Appl Environ Microbiol 2000 66 2578 2588 10.1128/AEM.66.6.2578-2588.2000 10831441 (Pubitemid 30353968)
24. Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. Marteau P, Pochart P, Flourié B, Pellier P, Santos L, Desjeux JF, Rambaud JC, Am J Clin Nutr 1990 52 685 688 2119557
25. Nutritional support in patients with acute pancreatitis. Piccinni G, Testini M, Angrisano A, Lissidini G, Gurrado A, Memeo R, Basile F, Biondi A, Front Biosci (Elite Ed) 2012 4 1999 2006 22202015
26. The effect of probiotic microorganisms and bioactive compounds on chemically induced carcinogenesis in rats. Bertkova I, Hijova E, Chmelarova A, Mojzisova G, Petrasova D, Strojny L, Bomba A, Zitnan R, Neoplasma 2010 57 422 428 10.4149/neo-2010-05-422 20568896
27. Mutagenic potency of food-derived heterocyclic amines. Felton JS, Knize MG, Wu RW, Colvin ME, Hatch FT, Malfatti MA, Mutat Res 2007 616 90 94 10.1016/j.mrfmmm.2006.11.010 17161439 (Pubitemid 46198866)
28. Formation and biochemistry of carcinogenic heterocyclic aromatic amines in cooked meats. Turesky RJ, Toxicol Lett 2007 168 219 227 10.1016/j.toxlet. 2006.10.018 17174486 (Pubitemid 46097341)
29. Metabolism of dietary genotoxins by the human colonic microflora; the fecapentaenes and heterocyclic amines. Van Tassell RL, Kingston DG, Wilkins TD, Mutat Res 1990 238 209 221 10.1016/0165-1110(90)90013-2 2160606
30. Food-derived mutagens and carcinogens. Wakabayashi K, Nagao M, Esumi H, Sugimura T, Cancer Res 1992 52 2092s 2098s 1544146
31. Cancer-preventing attributes of probiotics: an update. Kumar M, Kumar A, Nagpal R, Mohania D, Behare P, Verma V, Kumar P, Poddar D, Aggarwal PK, Henry CJ, Jain S, Yadav H, Int J Food Sci Nutr 2010 61 473 496 10.3109/ 09637480903455971 20187714
32. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. Orrhage K, Sillerström E, Gustafsson JA, Nord CE, Rafter J, Mutat Res 1994 311 239 248 10.1016/0027-5107(94)90182-1 7526189 (Pubitemid 24357450)
33. Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. Ragusa M, Statello L, Maugeri M, Majorana A, Barbagallo D, Salito L, Sammito M, Santonocito M, Angelica R, Cavallaro A, Scalia M, Caltabiano R, Privitera G, Biondi A, Di Vita M, Cappellani A, Vasquez E, Lanzafame S, Tendi E, Celeste S, Di Pietro C, Basile F, Purrello M, J Mol Med (Berl)
34. The antimutagenic properties of a polysaccharide produced by Bifidobacterium longum and its cultured milk against some heterocyclic amines. Sreekumar O, Hosono A, Can J Microbiol 1998 44 1029 1036 10029998
35. The heterocyclic amine binding receptors of Lactobacillus gasseri cells. Sreekumar O, Hosono A, Mutat Res 1998 421 65 72 10.1016/S0027-5107(98)00155-9 9748508 (Pubitemid 29039288)
36. Effects of lactic acid bacteria on the uptake and distribution of the food mutagen Trp-P-2 in mice. Orrhage KM, Annas A, Nord CE, Brittebo EB, Rafter JJ, Scand J Gastroenterol 2002 37 215 221 10.1080/003655202753416902 11843060 (Pubitemid 34103012)
37. Antimutagenicity of cell fractions of microorganisms on potent mutagenic pyrolysates. Zhang XB, Ohta Y, Mutat Res 1993 298 247 253 10.1016/0165-1218(93) 90003-V 7678160 (Pubitemid 23021128)
38. Antimutagenicity and the influence of physical factors in binding Lactobacillus gasseri and Bifidobacterium longum cells to amino acid pyrolysates. Sreekumar O, Hosono A, J Dairy Sci 1998 81 1508 1516 10.3168/jds.S0022-0302(98)75716-9 9684159 (Pubitemid 128449298)
39. Three glycoproteins with antimutagenic activity identified in Lactobacillus plantarum KLAB21. Rhee CH, Park HD, Appl Environ Microbiol 2001 67 3445 3449 10.1128/AEM.67.8.3445-3449.2001 11472917 (Pubitemid 33641212)
40. Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats. Challa A, Rao DR, Chawan CB, Shackelford L, Carcinogenesis 1997 18 517 521 10.1093/carcin/18.3.517 9067551 (Pubitemid 28132489)
41. Microbial-gut interactions in health and disease. Prebiotics. Manning TS, Gibson GR, Best Pract Res Clin Gastroenterol 2004 18 287 298 10.1016/j.bpg.2003.10.008 15123070 (Pubitemid 38444131)
42. Role of bile acids in colorectal carcinogenesis. Nagengast FM, Grubben MJ, van Munster IP, Eur J Cancer 1995 31A 1067 1070 10.1016/0959-8049(95)00216-6 7576993
43. Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Merchant BN, Rogers CM, Trivedi B, Morrow J, Coffey RJ, Surgery 2005 138 415 421 10.1016/j.surg.2005.06. 030 16213893 (Pubitemid 41415567)
44. Factors influencing the development of sigmoid colon cancer. Bacteriologic and biochemical studies. Kanazawa K, Konishi F, Mitsuoka T, Terada A, Itoh K, Narushima S, Kumemura M, Kimura H, Cancer 1996 77 1701 1706 8608565 (Pubitemid 26111855)
45. Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Huycke MM, Gaskins HR, Exp Biol Med (Maywood) 2004 229 586 597 15229352 (Pubitemid 38885671)
46. Hydrogen sulfide induces direct radical-associated DNA damage. Attene-Ramos MS, Wagner ED, Gaskins HR, Plewa MJ, Mol Cancer Res 2007 5 455 459 10.1158/1541-7786.MCR-06-0439 17475672 (Pubitemid 46903954)
47. Microbial dysbiosis in colorectal cancer (CRC) patients. Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Tran Van Nhieu J, Furet JP, PLoS One 2011 6 16393 10.1371/journal.pone.0016393 21297998
48. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, Klinder A, O'Riordan M, O'Sullivan GC, Pool-Zobel B, Rechkemmer G, Roller M, Rowland I, Salvadori M, Thijs H, Van Loo J, Watzl B, Collins JK, Am J Clin Nutr 2007 85 488 496 17284748 (Pubitemid 46220953)
49. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. O'Mahony L, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O'Sullivan G, Shanahan F, Collins JK, Aliment Pharmacol Ther 2001 15 1219 1225 10.1046/j.1365-2036.2001.01027.x 11472326 (Pubitemid 32675457)
50. The role of nutrition in the development of esophageal cancer: what do we know? Berretta M, Lleshi A, Fisichella R, Berretta S, Basile F, Li Volti G, Bolognese A, Biondi A, De Paoli P, Tirelli U, Cappellani A, Front Biosci (Elite Ed) 2012 4 351 7 22201877
51. Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants. Trejo FM, Minnaard J, Perez PF, De Antoni GL, Anaerobe 2006 12 186 193 10.1016/j.anaerobe.2006.03.004 16759886 (Pubitemid 44331635)
52. Tumor escape from immune response: mechanisms and targets of activity. Gabrilovich D, Pisarev V, Curr Drug Targets 2003 4 525 536 10.2174/ 1389450033490849 14535653 (Pubitemid 37139048)
53. A new morphologically characterized cell wall preparation [whole peptidoglycan] from Bifidobacterium infantis with a higher efficacy on the regression of an established tumor in mice. Sekine K, Toida T, Saito M, Kuboyama M, Kawashima T, Hashimoto Y, Cancer Res 1985 45 1300 1307 3971375 (Pubitemid 15111296)
54. Antitumor effect of Lactobacillus casei (LC 9018). Yokokura T, Kato I, Mutai M, Intestinal flora and carcinogenesis Gakkai-Syuppan Center Tokyo, Japan, Mitsuoka T, 1981 72 88
55. Antitumor activity of Lactobacillus casei in mice. Kato I, Kobayashi S, Yokokura T, Mutai M, Gann 1981 72 517 523 6796451 (Pubitemid 11056171)
56. Anti-tumour activity of Lactobacillus casei on Lewis lung carcinoma and line-10 hepatoma in syngeneic mice and guinea pigs. Matsuzaki T, Yokokura T, Azuma I, Cancer Immunol Immunother 1985 20 18 22 3933816 (Pubitemid 15238918)
57. Protective effect of Lactobacillus casei on Pseudomonas aeruginosa infection in mice. Miake S, Nomoto K, Yokokura T, Yoshikai Y, Mutai M, Nomoto K, Infect Immun 1985 48 480 485 3921464 (Pubitemid 15097722)
58. Antitumor effect of intrapleural administration of Lactobacillus casei in mice. Matsuzaki T, Yokokura T, Mutai M, Cancer Immunol Immunother 1988 26 209 214 3133110
59. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S, Eur Urol 1995 27 104 109 7744150
60. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group. Aso Y, Akazan H, Urol Int 1992 49 125 129 10.1159/000282409 1466089
61. Immunomodulation by treatment with Lactobacillus casei strain Shirota. Matsuzaki T, Int J Food Microbiol 1998 41 133 140 10.1016/S0168-1605(98)00046-4 9704862 (Pubitemid 28369427)
62. Probiotics in the gastrointestinal diseases of the elderly. Malaguarnera G, Leggio F, Vacante M, Motta M, Giordano M, Biondi A, Basile F, Mastrojeni S, Mistretta A, Malaguarnera M, Toscano MA, Salmeri M, J Nutr Health Aging 2012 16 402 10 10.1007/s12603-011-0357-1 22499466
63. Inhibitory effect of oral administration of Lactobacillus casei on 3-methylcholanthrene-induced carcinogenesis in mice. Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M, Yokokura T, Med Microbiol Immunol 1999 188 111 116 10.1007/s004300050112 10776840 (Pubitemid 30085356)
64. Induction of colorectal cancer in rats by 20-methylcholanthrene. Baral RN, Maity P, Cancer Lett 1992 61 177 183 10.1016/0304-3835(92)90177-W 1730142
65. Modulation of methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse by indomethacin. Rao AR, Hussain SP, Cancer Lett 1988 43 15 19 10.1016/0304-3835(88)90206-6 3203324 (Pubitemid 19006390)
66. Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M, Yokokura T, Carcinogenesis 2001 22 599 605 10.1093/carcin/22.4.599 11285195 (Pubitemid 32288661)
67. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K, Lancet 2000 356 1795 1799 10.1016/S0140- 6736(00)03231-1 11117911
68. A key role of dendritic cells in probiotic functionality. Foligne B, Zoumpopoulou G, Dewulf J, Ben Younes A, Chareyre F, Sirard JC, Pot B, Grangette C, PLoS One 2007 2 313 10.1371/journal.pone.0000313
69. Dendritic cells and the control of immunity. Banchereau J, Steinman RM, Nature 1998 392 245 252 10.1038/32588 9521319 (Pubitemid 28155090)
70. Immunomodulatory function of lactic acid bacteria. Yasui H, Shida K, Matsuzaki T, Yokokura T, Antonie Van Leeuwenhoek 1999 76 383 389 10.1023/A:1002041616085 10532394 (Pubitemid 29440742)
71. Relationship between the in vitro response of dendritic cells to Lactobacillus and prevention of tumorigenesis in the mouse. Takagi A, Ikemura H, Matsuzaki T, Sato M, Nomoto K, Morotomi M, Yokokura T, J Gastroenterol 2008 43 661 669 10.1007/s00535-008-2212-7 18807127
72. A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. Matsumoto S, Hara T, Nagaoka M, Mike A, Mitsuyama K, Sako T, Yamamoto M, Kado S, Takada T, Immunology 2009 128 170 180 10.1111/j.1365-2567.2008.02942.x 19740306
73. Immunomodulatory and antitumor effects in vivo by the cytoplasmic fraction of Lactobacillus casei and Bifidobacterium longum. Lee JW, Shin JG, Kim EH, Kang HE, Yim IB, Kim JY, Joo HG, Woo HJ, J Vet Sci 2004 5 41 48 15028884
74. Apoptosis: a review of programmed cell death. Elmore S, Toxicol Pathol 2007 35 495 516 10.1080/01926230701320337 17562483 (Pubitemid 46911891)
75. Promoting apoptosis as a strategy for cancer drug discovery. Fesik SW, Nat Rev Cancer 2005 5 876 885 10.1038/nrc1736 16239906 (Pubitemid 41746032)
76. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. Iyer C, Kosters A, Sethi G, Kunnumakkara AB, Aggarwal BB, Versalovic J, Cell Microbiol 2008 10 1442 1452 10.1111/j.1462-5822.2008.01137.x 18331465 (Pubitemid 351837265)
77. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Otte JM, Mahjurian-Namari R, Brand S, Werner I, Schmidt WE, Schmitz F, Nutr Cancer 2009 61 103 113 10.1080/01635580802372625 19116880
78. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T, Cancer Res 1995 55 3785 3789 7641194
79. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Tsujii M, DuBois RN, Cell 1995 83 493 501 10.1016/0092-8674(95)90127-2 8521479
80. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Chan TA, Morin PJ, Vogelstein B, Kinzler KW, Proc Natl Acad Sci U S A 1998 95 681 686 10.1073/pnas.95.2.681 9435252 (Pubitemid 28083803)
81. A synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. Le Leu RK, Brown IL, Hu Y, Bird AR, Jackson M, Esterman A, Young GP, J Nutr 2005 135 996 1001 15867271 (Pubitemid 40638297)
82. Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Baricault L, Denariaz G, Houri JJ, Bouley C, Sapin C, Trugnan G, Carcinogenesis 1995 16 245 252 10.1093/carcin/16.2.245 7859355
83. In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects. Grimoud J, Durand H, de Souza S, Monsan P, Ouarné F, Theodorou V, Roques C, Int J Food Microbiol 2010 144 42 50 10.1016/j.ijfoodmicro.2010.09.007 20951454
84. Rapid identification of differentiation markers from whole epithelial cells by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry and statistical analysis. Marvin-Guy LF, Duncan P, Wagnière S, Antille N, Porta N, Affolter M, Kussmann M, Rapid Commun Mass Spectrom 2008 22 1099 1108 10.1002/rcm.3479 18335464 (Pubitemid 351600757)
85. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N, Reddy BS, Carcinogenesis 1997 18 833 841 10.1093/carcin/18.4.833 9111222 (Pubitemid 28132475)
86. Assessment of ornithine decarboxylase activity in rectal mucosa as a marker for colorectal adenomas and carcinomas. Moorehead RJ, Hoper M, McKelvey ST, Br J Surg 1987 74 364 365 10.1002/bjs.1800740513 3594125 (Pubitemid 17080883)
87. Dietary modification of the intestinal microbiota. Mai V, Nutr Rev 2004 62 235 242 10.1111/j.1753-4887.2004.tb00045.x 15291396 (Pubitemid 38916068)
88. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Topping DL, Clifton PM, Physiol Rev 2001 81 1031 1064 11427691 (Pubitemid 32611227)
89. Effects of short chain fatty acids on a new human colon carcinoma cell line (LIM1215). Whitehead RH, Young GP, Bhathal PS, Gut 1986 27 1457 1563 10.1136/gut.27.12.1457 3804021
90. Colonic fermentation of dietary fibre to short chain fatty acids in patients with adenomatous polyps and colonic cancer. Clausen MR, Bonnén H, Mortensen PB, Gut 1991 32 923 928 10.1136/gut.32.8.923 1653178
91. Faecal pH, dietary fibre intake, and proneness to colon cancer in four South African populations. Walker AR, Walker BF, Walker AJ, Br J Cancer 1986 53 489 495 10.1038/bjc.1986.77 3011051 (Pubitemid 16111965)
92. Oral administration of butyrivibrio fibrisolvens, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice. Ohkawara S, Furuya H, Nagashima K, Asanuma N, Hino T, J Nutr 2005 135 2878 2883 16317136 (Pubitemid 43156557)
93. Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propionibacteria. Lan A, Lagadic-Gossmann D, Lemaire C, Brenner C, Jan G, Apoptosis 2007 12 573 591 10.1007/s10495-006-0010- 3 17195096
94. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Jan G, Belzacq AS, Haouzi D, Rouault A, Métivier D, Kroemer G, Brenner C, Cell Death Differ 2002 9 179 188 10.1038/sj.cdd.4400935 11840168 (Pubitemid 34144777)
95. Fermented wheat aleurone enriched with probiotic strains LGG and Bb12 modulates markers of tumor progression in human colon cells. Borowicki A, Michelmann A, Stein K, Scharlau D, Scheu K, Obst U, Glei M, Nutr Cancer 2011 63 151 160 21161821
96. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. Evans NP, Misyak SA, Schmelz EM, Guri AJ, Hontecillas R, Bassaganya-Riera J, J Nutr 2010 140 515 521 10.3945/jn.109.115642 20089779
97. Conjugated linoleic acid isomers and cancer. Kelley NS, Hubbard NE, Erickson KL, J Nutr 2007 137 2599 2607 18029471 (Pubitemid 350255285)
98. Dietary supplementation of conjugated linoleic acid reduces colon tumor incidence in DMH-treated rats by increasing apoptosis with modulation of biomarkers. Kim KH, Park HS, Nutrition 2003 19 772 777 10.1016/S0899-9007(03) 00098-4 12921888 (Pubitemid 36961390)
99. Protection of conjugated linoleic acids against 2-amino-3- methylimidazo[4,5-f]quinoline-induced colon carcinogenesis in the F344 rat: a study of inhibitory mechanisms. Liew C, Schut HA, Chin SF, Pariza MW, Dashwood RH, Carcinogenesis 1995 16 3037 3043 10.1093/carcin/16.12.3037 8603482
100. Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. Ewaschuk JB, Walker JW, Diaz H, Madsen KL, J Nutr 2006 136 1483 1487 16702308 (Pubitemid 43765349)
101. Cell signaling by receptor tyrosine kinases. Lemmon MA, Schlessinger J, Cell 2010 141 1117 1134 10.1016/j.cell.2010.06.011 20602996
102. The place of probiotics in human intestinal infections. Sullivan A, Nord CE, Int J Antimicrob Agents 2002 20 313 319 10.1016/S0924-8579(02)00199-1 12431865 (Pubitemid 35300426)
103. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Guslandi M, Mezzi G, Sorghi M, Testoni PA, Dig Dis Sci 2000 45 1462 1464 10.1023/A:1005588911207 10961730 (Pubitemid 30636526)
104. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P, Infect Immun 2000 68 5998 6004 10.1128/IAI.68.10.5998-6004.2000 10992512
105. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3',5'-cyclic monophosphate induction in intestinal cells. Czerucka D, Roux I, Rampal P, Gastroenterology 1994 106 65 72 8276210
106. ErbB receptors and signaling pathways in cancer. Hynes NE, MacDonald G, Curr Opin Cell Biol 2009 21 177 184 10.1016/j.ceb.2008.12.010 19208461
107. Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Chen X, Fruehauf J, Goldsmith JD, Xu H, Katchar KK, Koon HW, Zhao D, Kokkotou EG, Pothoulakis C, Kelly CP, Gastroenterology 2009 137 914 923 10.1053/j.gastro.2009.05.050 19482027
108. ApcMin: a mouse model for intestinal and mammary tumorigenesis. Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF, Eur J Cancer 1995 31A 1061 1064 10.1016/0959-8049(95)00181-H 7576992
109. The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. Ma EL, Choi YJ, Choi J, Pothoulakis C, Rhee SH, Im E, Int J Cancer 2010 127 780 790 19876926
110. Diet and cancer: assessing the risk. Gill CI, Rowland IR, Br J Nutr 2002 88 73 87 10.1079/BJN2002585 12117430
111. PASSCLAIM - diet-related cancer. Rafter J, Govers M, Martel P, Pannemans D, Pool-Zobel B, Rechkemmer G, Rowland I, Tuijtelaars S, van Loo J, Eur J Nutr 2004 43 I47 II84 15221354